**Claims**

1. Use of ~~A~~ a pharmaceutical composition comprising a compound and at least one pharmaceutically acceptable excipient for the preparation of a medicament for sequestering one or more antibodies present in an individual; wherein the compound ~~comprising~~comprises

- a biopolymer scaffold and at least
- a first peptide n-mer of the general formula:

$$\mathbf{P\ (\ -\ S\ -\ P\ )_{(n-1)}}$$ and

- a second peptide n-mer of the general formula:

$$\mathbf{P\ (\ -\ S\ -\ P\ )_{(n-1)}\ ;}$$

wherein, independently for each occurrence, P is a peptide with a sequence length of 2-13 amino acids, preferably 3-11 amino acids, more preferably 4-9 amino acids, especially 5-8 amino acids, and S is a non-peptide spacer,

wherein, independently for each of the peptide n-mers, n is an integer of at least 1, preferably of at least 2, more preferably of at least 3, especially of at least 4,

wherein each of the peptide n-mers is bound to the biopolymer scaffold, preferably via a linker each;

wherein the biopolymer scaffold is a ~~human~~ protein selected from the group consisting of albumins and globulins and

wherein at least one occurrence of P is a circularized peptide;

wherein the composition is non-immunogenic in the individual and wherein the one or more antibodies present in the individual are specific for at least one occurrence of peptide P.

2. The ~~compound~~ use of claim 1, wherein at least 10% of all occurrences of P are circularized peptides, more preferably wherein at least 25% of all occurrences of P are circularized peptides, yet more preferably wherein at least 50% of all occurrences of P are circularized peptides, even more preferably wherein at least 75% of all occurrences of P are circularized peptides, yet even more preferably wherein at least 90% of all occurrences of P are circularized peptides or even wherein at least 95% of all occurrences of P are circularized peptides,

especially wherein all of the occurrences of P are circularized peptides.

3. The ~~compound~~ use of claim 1 or 2, wherein, independently for each occurrence, P is $P_a$ or $P_b$,

wherein $P_a$ is a peptide with a sequence length of 2-13 amino acids, preferably 3-11 amino acids, more preferably 4-9 amino acids, especially 5-8 amino acids,

wherein $P_b$ is a peptide with a sequence length of 2-13 amino acids, preferably 3-11 amino acids, more preferably 4-9 amino acids, especially 5-8 amino acids; and wherein

the first peptide n-mer is **$P_a$ – S – $P_a$** and the second peptide n-mer is **$P_a$ – S – $P_a$** ,

the first peptide n-mer is **$P_a$ – S – $P_a$** and the second peptide n-mer is **$P_b$ – S – $P_b$** ,

the first peptide n-mer is **$P_b$ – S – $P_b$** and the second peptide n-mer is **$P_b$ – S – $P_b$** ,

the first peptide n-mer is **$P_a$ – S – $P_b$** and the second peptide n-mer is **$P_a$ – S – $P_b$** ,

the first peptide n-mer is **$P_a$ – S – $P_b$** and the second peptide n-mer is **$P_a$ – S – $P_a$** , or

the first peptide n-mer is **$P_a$ – S – $P_b$** and the second peptide n-mer is **$P_b$ – S – $P_b$**.

4. The ~~compound~~ use of claim 3, wherein the peptide $P_a$ and the peptide $P_b$ are two different epitopes of the same antigen or two different epitope parts of the same epitope.

5. The ~~compound~~ use of any one of claims 1 to 4, wherein the biopolymer scaffold is selected from the group consisting of albumins, alpha1-globulins, alpha2-globulins and beta-globulins, in particular wherein the biopolymer scaffold is albumin, haptoglobin or transferrin~~, especially haptoglobin~~.

6. The ~~compound~~ use of any one of claims 1 to 5, wherein the ~~compound is non-immunogenic in~~individual is a mammal, preferably ~~in~~ a human, ~~in~~ a non-human primate, ~~in~~ a sheep, ~~in~~ a pig, ~~in~~ a dog or ~~in~~ a rodent.

~~7. A pharmaceutical composition comprising the compound of any one of claims 1 to 6 and at least one pharmaceutically acceptable excipient.~~

~~8~~7. The ~~pharmaceutical composition of~~use of claim ~~7~~6, wherein the ~~composition~~ individual is ~~non-immunogenic in~~a human~~s~~.

~~9. The pharmaceutical composition of claim 7 or 8 for use in therapy.~~

~~10~~8. ~~The pharmaceutical composition for use according to claim 9~~The use of any one of claims 1 to 7, ~~for use in~~further for prevention or treatment of an autoimmune disease, ~~in an~~wherein the individual ~~having~~ has the autoimmune disease or ~~being~~ is at risk of developing the autoimmune disease.

~~11~~9. ~~The pharmaceutical composition for use according to claim 9~~The use of any one of claims 1 to 7, ~~for use in~~further for prevention or treatment of transplant rejection in an individual having a transplant or eligible for a transplantation.

~~12~~10. ~~The pharmaceutical composition for use according to claim 9~~The use of any one of claims 1 to 7, ~~for use in~~further for prevention or treatment of adverse reactions based on anti-drug antibodies or anti-gene-delivery vector antibodies, in particular anti-AAV antibodies, ~~in an~~wherein the individual ~~undergoing~~ undergoes therapy with the drug or is eligible for therapy with the drug, or ~~in~~ wherein the~~an~~ individual ~~undergoing~~ undergoes gene therapy or is eligible for gene therapy,

preferably wherein the drug is a peptide or protein, especially selected from the group of enzymes, enzyme inhibitors, antibodies, antibody fragments, antibody mimetics, antibody-drug conjugates, hormones, growth factors, clotting factors and cytokines, preferably wherein the entire sequence, optionally with the exception of an N-terminal and/or C-terminal cysteine, of at least one occurrence of peptide P~~, or of peptide $P_a$ and/or of peptide $P_b$~~ is identical to a sequence fragment of an amino-acid sequence of the peptide or protein, optionally wherein said sequence fragment comprises at most five, preferably at most four, more preferably at most three, even more preferably at most two, especially at most one amino acid substitutions.

~~13. A method of sequestering one or more antibodies present in an individual, comprising~~

~~obtaining a pharmaceutical composition as defined in claims 7 or 8, wherein the composition is non-immunogenic in the individual and wherein the one or more antibodies present in the individual are specific for at least one occurrence of P, or for peptide $P_a$ and/or peptide $P_b$; and~~

~~administering the pharmaceutical composition to the individual.~~

~~14. A pharmaceutical composition, comprising the compound of any one of claims 1 to 6 and further comprising an active agent such as a protein or a peptide and optionally at least one pharmaceutically acceptable excipient,~~

~~wherein the active agent comprises a peptide fragment with a sequence length of 2-13 amino acids, preferably 3-11 amino acids, more preferably 4-9 amino acids, especially 5-8 amino acids, and~~

~~wherein the sequence of at least one occurrence of peptide P, or peptide $P_a$ and/or peptide $P_b$, of the compound is at least 70% identical, preferably at least 75% identical, more preferably at least 80% identical, yet more preferably at least 85% identical, even more preferably at least 90% identical, yet even more preferably at least 95% identical, especially completely identical to the sequence of said peptide fragment.~~

~~15. A method of inhibiting an immune reaction to a treatment with an active agent in an individual in need of treatment with the active agent, comprising~~

~~obtaining a pharmaceutical composition as defined in claim 14; wherein the compound of the pharmaceutical composition is non-immunogenic in the individual, and~~

~~administering the pharmaceutical composition to the individual.~~